Senhwa Biosciences (ROCO:6492) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Senhwa Biosciences Debt-to-Asset?

Senhwa Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$7.16 Mil. Senhwa Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$7.84 Mil. Senhwa Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$1,065.96 Mil. Senhwa Biosciences's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

Senhwa Biosciences Debt-to-Asset Historical Data

The historical data trend for Senhwa Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senhwa Biosciences Debt-to-Asset Chart

Senhwa Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Senhwa Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.02	0.02	0.02	0.01

Competitive Comparison of Senhwa Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Senhwa Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senhwa Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Senhwa Biosciences's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Senhwa Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Senhwa Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.158	+	7.837)	/	1065.957
	=	0.01

Senhwa Biosciences's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.158	+	7.837)	/	1065.957
	=	0.01

Senhwa Biosciences (ROCO:6492) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Senhwa Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Senhwa Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Senhwa Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Senhwa Biosciences Inc (ROCO:6492) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Peihsin Road, 10th Floor, No. 225, Section 3, Hsintien District, New Taipei, TWN, 23143

Website

https://www.senhwabio.com

Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), Silmitasertib (CX-4945), and Silmitasertib (for Moderate Covid-19). All of its revenue comes from Taiwan.

Senhwa Biosciences Headlines

No Headlines